Blog Posts - Daiichi Sankyo



Eliquis, Savaysa, And Xarelto: New Blood Thinner Drugs Feared By Many Doctors Because No Antidote Is Available When Needed

Some Recent Articles Point Out the Real Problems And Consequences Of Major Bleeding Events Involving Eliquis, Savaysa, And Xarelto (Posted by Tom Lamb at DrugInjuryWatch.com) As many of you know from direct-to-consumer advertising on television, ther...
by Drug Injury Watch on Jan 7, 2016

A French Medical Study Provides More Support For Apparent Link Between Benicar With Chronic Severe Diarrhea And Substantial Weight Loss Side Effects

Researchers Found An Almost 10-Times Increased Risk Of Severe Intestinal Malabsorption Associated With Benicar After 2-Years Use Compared To Some Other Blood Pressure Medications (Posted by Tom Lamb at DrugInjuryWatch.com) We continue to hear about p...
by Drug Injury Watch on Jan 12, 2015

Benicar-Induced Enteropathy: Recently Found / New Possible Cause Of Villous Atrophy: Symptoms And Diagnosis

Chronic Or Severe Diarrhea With Damage To The Intestinal Villi And Malabsorption Indicate Sprue-Like Enteropathy (Posted by Tom Lamb at DrugInjuryWatch.com) An association between the oral angiotensin-receptor blocker (ARB) Benicar (olmesartan) and t...
by Drug Injury Watch on Feb 7, 2014

Investment Strategy – Ranbaxy Laboratories

Join Free intraday tips group and receive investment updates Join Free intraday tips group and receive investment updates Ranbaxy Laboratories in December 2011 signed a consent decree with the US Food and Dmg Administration (FDA), which is subject...
by Stock Advice on Jan 21, 2012

Daiichi Sankyo Logo Photos

Daiichi Sankyo Co., Ltd. is a global pharmaceutical company and the second largest pharmaceutical company in Japan.
by Symbols and Logos on Sep 28, 2011

Genome study brings blood cancer into sharp focus

Bio Technician demonstrates the loading of the high tech 454 Life Science sequencing machine in the sequencing laboratory at the J. Craig Venter Institute in Rockville, Maryland, in this March 29, 2010 file photo. Credit: Reuters/Larry Downing (U...
by Biopharma Investor on Mar 26, 2011

Japan: Over a 1000 have died and now a Nuclear Reactor in Trouble…

Today at 12:43 | Reuters SINGAPORE, March 12 (Reuters) – An explosion blew the roof off an unstable nuclear reactor north of Tokyo on Saturday and a government official confirmed a radiation leak had occurred at the plant, operated by Toky...
by The Silver People Chronicle on Mar 12, 2011

Daiichi Sankyo and ArQule Enroll First Non-Small Cell Lung Cancer Patient into Global Phase 3 Trial for ARQ 197

TOKYO and WOBURN, Mass.–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhi...
by Cancer Information Center on Jan 12, 2011

Comprehensive List of Drug Approvals From 2009

I found a nice list of all the drugs approved in 2009 and their respectable companies.Those of note were Glaxo SmithKline (GSK) with HPV vaccine, H1N1, seasonal flu vaccine, renal carcinoma, and lymphocyte leukemia.Novartis (NVS) for H1N1, seasonal f...
by Biopharma Investor on Sep 6, 2010

Is ArQule The Next Dendreon?

This stock has been on my radar for a couple of months. Arqule could be the next Dendreon. It is a cash cow and needs a little more clinical trial data before I pull the trigger but I will continue to watch this stock. I will keep you up to date if a...
by Biopharma Investor on Sep 6, 2010

FDA finally approves Effient (prasugrel)

The FDA has finally approved Effient (prasugrel), a thienopyridine that is similar to Plavix (clopidogrel). In fact, prasugrel has been compared to clopidogrel. The TRITON-TIMI 38 study (comparing prasugrel against clopidogrel) was published in the N...


Trending Topics

Close